These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14730652)

  • 41. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring the mechanisms of macrolides in cystic fibrosis.
    Equi AC; Davies JC; Painter H; Hyde S; Bush A; Geddes DM; Alton EW
    Respir Med; 2006 Apr; 100(4):687-97. PubMed ID: 16185859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosing and managing cystic fibrosis in the developing world.
    Kabra SK; Kabra M; Shastri S; Lodha R
    Paediatr Respir Rev; 2006; 7 Suppl 1():S147-50. PubMed ID: 16798545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The treatment of cystic fibrosis--step by step.
    Hazinski TA
    J Pediatr; 2001 Oct; 139(4):3A. PubMed ID: 11598588
    [No Abstract]   [Full Text] [Related]  

  • 47. What have we learned from mouse models for cystic fibrosis?
    Carvalho-Oliveira I; Scholte BJ; Penque D
    Expert Rev Mol Diagn; 2007 Jul; 7(4):407-17. PubMed ID: 17620048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic treatment of CF lung disease: from bench to bedside.
    Bals R; Hubert D; Tümmler B
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S146-51. PubMed ID: 21658633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence-based medicine in cystic fibrosis: how should practice change?
    Conway SP
    Pediatr Pulmonol; 2002 Sep; 34(3):242-7. PubMed ID: 12203857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Newer therapies for cystic fibrosis.
    Schidlow DV
    Paediatr Respir Rev; 2000 Jun; 1(2):107-13. PubMed ID: 12531102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy.
    Lopes SP; Azevedo NF; Pereira MO
    Crit Rev Microbiol; 2015; 41(3):353-65. PubMed ID: 24645634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Management of the patient with mucoviscidosis].
    ;
    Rev Mal Respir; 2003 Feb; 20(1 Pt 1):149-57. PubMed ID: 12739564
    [No Abstract]   [Full Text] [Related]  

  • 53. New treatment for cystic fibrosis.
    Kuhn RJ
    Am Pharm; 1994 Feb; NS34(2):16-8. PubMed ID: 8166040
    [No Abstract]   [Full Text] [Related]  

  • 54. The current management of cystic fibrosis.
    Lees CM; Smyth RL
    Int J Clin Pract; 2000 Apr; 54(3):171-9. PubMed ID: 10829360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biotechnology. Disease group invests in do-it-yourself drugs.
    Marshall E
    Science; 2000 Jun; 288(5472):1715-7. PubMed ID: 10877679
    [No Abstract]   [Full Text] [Related]  

  • 56. Aztreonam for inhalation solution, challenges to drug approval and integration into CF care.
    Goss CH; Bell SC
    J Cyst Fibros; 2013 Mar; 12(2):99-101. PubMed ID: 22999443
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of azithromycin in patients with cystic fibrosis.
    Yousef AA; Jaffe A
    Paediatr Respir Rev; 2010 Jun; 11(2):108-14. PubMed ID: 20416547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and adverse effects of drugs used to treat adult cystic fibrosis.
    Chopra R; Paul L; Manickam R; Aronow WS; Maguire GP
    Expert Opin Drug Saf; 2015 Mar; 14(3):401-11. PubMed ID: 25604518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pulmozyme (Dornase alfa)].
    Töglhofer W
    Wien Klin Wochenschr; 1994; 106(8):253-6. PubMed ID: 8023518
    [No Abstract]   [Full Text] [Related]  

  • 60. Dornase alfa approved for use by cystic fibrosis patients.
    Am J Hosp Pharm; 1994 Apr; 51(7):869-70. PubMed ID: 8017432
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.